{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:31:09Z","timestamp":1787614269367,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.semarthrit.2024.152500","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T18:12:32Z","timestamp":1719511952000},"page":"152500","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis"],"prefix":"10.1016","volume":"68","author":[{"given":"Chenghua","family":"Weng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongnan","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leixi","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhichun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10354","key":"10.1016\/j.semarthrit.2024.152500_bib0001","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"Wijsenbeek","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2024.152500_bib0002","doi-asserted-by":"crossref","first-page":"h6819","DOI":"10.1136\/bmj.h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152500_bib0003","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s40744-023-00540-6","article-title":"Clinical characteristics of dermatomyositis with interstitial lung disease: a retrospective case-control study","volume":"10","author":"Weng","year":"2023","journal-title":"Rheumatol Ther"},{"key":"10.1016\/j.semarthrit.2024.152500_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17534666221117002","article-title":"Immunomodulatory treatment of interstitial lung disease","volume":"16","author":"van den Bosch","year":"2022","journal-title":"Ther Adv Respir Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00296-019-04481-8","article-title":"Effect of mycophenolate mofetil (MMF) on systemic sclerosis-related interstitial lung disease with mildly impaired lung function: a double-blind, placebo-controlled, randomized trial","volume":"40","author":"Naidu","year":"2020","journal-title":"Rheumatol Int"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152500_bib0006","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00296-020-04565-w","article-title":"Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial","volume":"40","author":"Acharya","year":"2020","journal-title":"Rheumatol Int"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152500_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9082560","article-title":"Efficacy, safety, and tolerability of treatments for systemic sclerosis-related interstitial lung disease: a systematic review and network meta-analysis","volume":"9","author":"Erre","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152500_bib0008","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respirat Med"},{"issue":"6","key":"10.1016\/j.semarthrit.2024.152500_bib0009","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1002\/art.42075","article-title":"Nintedanib in patients with autoimmune disease-related progressive fibrosing interstitial lung diseases: subgroup analysis of the INBUILD Trial","volume":"74","author":"Matteson","year":"2022","journal-title":"Arthrit Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0010","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jrsm.1037","article-title":"Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool","volume":"3","author":"Salanti","year":"2012","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.semarthrit.2024.152500_bib0011","doi-asserted-by":"crossref","DOI":"10.1177\/1759720X21999564","article-title":"Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis","volume":"13","author":"Weng","year":"2021","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152500_bib0012","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ophtha.2015.09.005","article-title":"Comparative effectiveness of first-line medications for primary open-angle glaucoma: a systematic review and network meta-analysis","volume":"123","author":"Li","year":"2016","journal-title":"Ophthalmology"},{"issue":"4","key":"10.1016\/j.semarthrit.2024.152500_bib0013","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.13613","article-title":"The effects of incretin-based therapies on \u03b2-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials","volume":"21","author":"Wu","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/jrsm.1044","article-title":"Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies","volume":"3","author":"Higgins","year":"2012","journal-title":"Res Synth Methods"},{"issue":"7\u20138","key":"10.1016\/j.semarthrit.2024.152500_bib0015","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152500_bib0016","doi-asserted-by":"crossref","first-page":"e76654","DOI":"10.1371\/journal.pone.0076654","article-title":"Graphical tools for network meta-analysis in STATA","volume":"8","author":"Chaimani","year":"2013","journal-title":"PLoS ONE"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152500_bib0017","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1007\/s10067-021-05794-5","article-title":"Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"40","author":"Ma","year":"2021","journal-title":"Clin Rheumatol"},{"issue":"Suppl 125(3)","key":"10.1016\/j.semarthrit.2024.152500_bib0018","first-page":"161","article-title":"Intravenous versus oral cyclophosphamide for lung and\/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials","volume":"38","author":"Bruni","year":"2020","journal-title":"Clin Exp Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152500_bib0019","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1002\/1529-0131(199810)41:10<1835::AID-ART16>3.0.CO;2-Q","article-title":"Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitis and renal involvement: a prospective, randomized study","volume":"41","author":"Haubitz","year":"1998","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152500_bib0020","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-124-5-199603010-00003","article-title":"Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis","volume":"124","author":"Talar-Williams","year":"1996","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152500_bib0021","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respirat Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152500_bib0022","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1093\/rheumatology\/key213","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatology"},{"issue":"22","key":"10.1016\/j.semarthrit.2024.152500_bib0023","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"9779","key":"10.1016\/j.semarthrit.2024.152500_bib0024","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","article-title":"Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials","volume":"377","author":"Noble","year":"2011","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152500_bib0025","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1002\/art.27466","article-title":"Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis","volume":"62","author":"Seibold","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152500_bib0026","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3899\/jrheum.161040","article-title":"Pomalidomide in patients with interstitial lung disease due to systemic sclerosis: a Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group Study","volume":"45","author":"Hsu","year":"2018","journal-title":"J Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2024.152500_bib0027","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1136\/annrheumdis-2019-216823","article-title":"Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial","volume":"79","author":"Khanna","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152500_bib0028","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3899\/jrheum.191365","article-title":"STRATUS: a Phase II study of abituzumab in patients with systemic sclerosis-associated interstitial lung disease","volume":"48","author":"Khanna","year":"2021","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152500_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0030","first-page":"348","article-title":"Use of Janus kinase inhibitors in dermatomyositis: a systematic literature review","volume":"41","author":"Paik","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0031","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/14397595.2019.1696505","article-title":"New indication for systemic sclerosis-associated interstitial lung disease","volume":"30","author":"Kuwana","year":"2020","journal-title":"Mod Rheumatol"},{"issue":"22","key":"10.1016\/j.semarthrit.2024.152500_bib0032","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semarthrit.2024.152500_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102403","article-title":"Is there today a place for corticosteroids in the treatment of scleroderma?","volume":"18","author":"Blagojevic","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.semarthrit.2024.152500_bib0034","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12931-022-02292-3","article-title":"Expert consensus on the management of systemic sclerosis-associated interstitial lung disease","volume":"24","author":"Rahaghi","year":"2023","journal-title":"Respir Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0035","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.autrev.2018.07.013","article-title":"Treatment of idiopathic inflammatory myositis associated interstitial lung disease: a systematic review and meta-analysis","volume":"18","author":"Barba","year":"2019","journal-title":"Autoimmun Rev"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0036","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/rheumatology\/keaa550","article-title":"Rituximab in the treatment of systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis","volume":"60","author":"Goswami","year":"2021","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.semarthrit.2024.152500_bib0037","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1159\/000508540","article-title":"Azathioprine for connective tissue disease-associated interstitial lung disease","volume":"99","author":"Boerner","year":"2020","journal-title":"Respiration"},{"issue":"2","key":"10.1016\/j.semarthrit.2024.152500_bib0038","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.semarthrit.2024.152500_bib0039","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2024.152500_bib0040","article-title":"Efficacy and safety of nintedanib in patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): a real-world single center experience","volume":"13","author":"Boutel","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"10","key":"10.1016\/j.semarthrit.2024.152500_bib0041","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s10067-023-06689-3","article-title":"Real world experience with nintedanib in connective tissue disease-related interstitial lung disease: a retrospective cohort study","volume":"42","author":"Bare\u0161i\u0107","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2024.152500_bib0042","article-title":"The efficacy and safety of pirfenidone combined with immunosuppressant therapy in connective tissue disease-associated interstitial lung disease: a 24-week prospective controlled cohort study","volume":"9","author":"Wang","year":"2022","journal-title":"Front Med"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001409?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017224001409?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T00:14:02Z","timestamp":1726618442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017224001409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":42,"alternative-id":["S0049017224001409"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152500","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152500","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152500"}}